
Gaetano Zizzo, Philip L Cohen*
Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA
10.1136/lupus-2018-lsm.105

Background Mer receptor tyrosine kinase (MerTK) is key for efficient phagocytosis of apoptotic neutrophils (ANs) and homeostasis of IL-10 production by human anti-inflammatory M2c monocytes/macrophages. We asked whether stimulation of certain M2c surface receptors contribute in turn to MerTK activation.

Methods Human monocytes/macrophages were differentiated under M1, M2a and M2c polarizing conditions. We tested the effects of antibody-mediated cross-linking of M2c receptors (i.e., CD14, CD16, CD32, CD163, CD204) on MerTK phosphorylation and phagocytosis of ANs. MerTK expression was also studied by flow cytometry and western blot in the presence of LPS and in M2c-derived microvesicles (MVs).

Results Antibody cross-linking of either CD14 or CD32/FcγRII led to Syk activation and MerTK phosphorylation in its two distinct glycoforms (175–205 and 135–153 KDa). Cross-linked CD14 enhanced efferocytosis by M2c macrophages and enabled M1 and M2a cells to clear ANs efficiently. In M1 conditions, LPS abolished surface MerTK expression on CD14-high cell subsets, so disrupting the anti-inflammatory pathway. In M2c cells, instead, MerTK was diffusely and brightly co-expressed with CD14, and was also detected in M2c macrophage-derived MVs; in these conditions, LPS only partially down-regulated MerTK on the cell surface, while the smaller MerTK glycoform contained in MVs remained intact. Co-Activation between CD14 and MerTK fosters tethering and engulfment of ANs by human monocytes/macrophages. CD14 stands between M1-related LPS co-receptor activity and M2c-related MerTK-dependent responses. MerTK interaction with CD32/FcγRII, its detection in M2c MVs, and the differential localization and LPS susceptibility of MerTK glycoforms add further new elements to the complexity of the MerTK network.

Acknowledgements NIAID and Lupus Research Alliance

II-07 PATHOGENESIS OF PULMONARY LUPUS AND VASCULITIS: TRAFFICKING OF INNATE B1 B CELLS TO THE LUNGS AS A NOVEL MECHANISM

1,2,4Ram R Singh*, 1Priti Prasad, 3Michael Fithian, 1Isela Valera. 1Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine; 2Molecular Toxicology Interdepartmental Program; 3Department of Pathology and Laboratory Medicine; 4Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, USA
10.1136/lupus-2018-lsm.106

Background Up to 50% patients with SLE may develop pneumonitis, vasculitis and diffuse pulmonary hemorrhage (DPH). Advances in the pathogenesis of pulmonary lupus have been hampered because of the heterogeneity of clinical findings and paucity of access to the affected tissue. Hydrocarbon oils, such as 2,6,10,14-tetramethylpentadecane (TMPD), induce lupus-like autoantibodies, nephritis, arthritis, pneumonitis, and DPH depending on the animals’ genetic background. Humans can be exposed to hydrocarbon oils in crude oil and in mineral oils used in cosmetics, laxatives, and food coatings. Here, we used this model to investigate the pathogenesis of pulmonary lupus, focusing on the role of innate B1 cells.

Methods We injected TMPD intraperitoneally in C57BL/6 (B6) mice to induce pulmonary lupus. We adoptively transferred wild-type peritoneal fluid cells which are enriched in B1 cells into CD19-/- (that have less B1a B-cells) and in Igμ-/- mice (have no B-cells), and tracked the transferred cells using CD45.1/CD45.2 system. Effect on disease was assessed using weight-loss, a semiquantitative scoring, and a quantitative measurement for lung hemorrhage. We analyzed global gene expression in the lungs using Affymatrix microarray.

Results In wild-type B6 mice, TMPD injection caused weight-loss, pneumonitis, vasculitis, and/or DPH in 73% of 62 animals compared to none of control animals injected with control hydrocarbon oil hexadecane or with PBS or sham. Immunophenotyping revealed abnormalities of all immune cells tested in the diseased lungs. At earlier timepoints prior to histopathological changes, while both hexadecane and TMPD caused myeloid cell abnormalities, only TMPD caused lung-infiltration with B-cells that expressed CD19+ and Igμ-/- mice induced more DPH/pneumonitis than the respective knockout recipients reconstituted with CD19-/- B-cells. The adoptive transfer of wildtype peritoneal fluid cells into the peritoneum of CD19+ or Igμ-/- mice induced more DPH/pneumonitis than the respective knockout recipients reconstituted with CD19-/- B-cells. The adoptive transfer of CD45.1+ wildtype peritoneal fluid cells into the peritoneum of CD45.2+CD19-/- recipients led to lung-infiltration with CD45.1 B-cells. Furthermore, TMPD induced in the lungs a differential expression of Cxcl13 that is known to drive B1 B-cells’ migration.

Conclusions Exposure to TMPD induces B1 B-cells to traffic from the peritoneum into the lungs and cause pneumonitis/ DPH. Identification of this mechanism in human lupus will have important implications for targeting a specific B-cell subset as a potential therapy.

II-08 COMPLEMENT RECEPTORS 1 AND 2 ON B CELL SUBSETS ARE NEGATIVELY ASSOCIATED WITH LUPUS DISEASE ACTIVITY

Shoshana Rosenthal, Dominik Reinhold, Kenneth L Jones, Weiming Zhang, Duane Pearson, Kara M Lough, Susan A Boackle*. University of Colorado School of Medicine, Aurora, CO
10.1136/lupus-2018-lsm.107

Background B cell complement receptor 1 (CR1) and complement receptor 2 (CR2) levels are decreased by ~50% in subjects with systemic lupus erythematosus (SLE). CR2 but not CR1 levels have been negatively correlated with lupus disease activity. However, increased CR1 expression on B cells is associated with a protective polymorphism in the CR2 gene. We conducted a longitudinal analysis of B cell CR1 and CR2 to further evaluate an association with lupus disease activity and to determine whether it is driven by specific cell subsets.

Methods Thirty-six subjects meeting the revised 1982 ACR criteria for SLE were enrolled. Each subject had a baseline